This supports, in part, PSAT1’s ability to promote cell migration under EGFR signaling, which may be a contributing determinant for its negative correlation with patient outcomes in EGFR-mutant NSCLC. The gene discussed is PSAT1; the disease is non-small cell lung carcinoma.